Xenotransplantation: Crossing Species to Bridge the Organ Gap
Summary of Medical Lecture by John J. Fung, MD, PhD
1. Main Clinical Topics Discussed
- Historical evolution and current state of xenotransplantation
- Immunological barriers to cross-species transplantation (hyperacute, antibody-mediated, and cell-mediated rejection)
- Non-human primate (NHP) xenotransplantation experience and its limitations
- Porcine xenotransplantation and genetically modified pig development
- Zoonotic infectious risks and regulatory considerations
- Current trajectory toward clinical trials using genetically modified pigs
2. Key Learning Points, Guidelines, and Recommendations
Definitions and Immunological Framework:
- Xenotransplantation: transplantation of tissues or organs between disparate species
- Discordant combinations (e.g., pig-to-human): primarily antibody-mediated rejection, driven by naturally occurring xenoreactive antibodies (predominantly IgM, some IgG) targeting the α-1,3-galactosyl (Gal) epitope on porcine endothelium
- Concordant combinations (e.g., NHP-to-human): more cell-mediated rejection with some antibody component; greater metabolic compatibility but significant ethical and infectious drawbacks
Non-Human Primate Donors — Advantages and Disadvantages:
- *Advantages*: genetic similarity, concordant rejection pattern, metabolic compatibility
- *Disadvantages*: limited availability, high cost, uncontrolled breeding environments, significant zoonotic risk, ethical concerns regarding humanization
- FDA imposed a moratorium on NHP donors in 1999 due to public health concerns
Porcine Donors — Rationale and Genetic Engineering Strategy:
- *Advantages*: readily available, easily bred, ethically justifiable (established food stock use), amenable to transgenic modification
- *Disadvantages*: discordant rejection pattern, protein incompatibility
- Key genetic modification strategies:
- Alpha-1,3-galactosyltransferase (GalT) gene knockout — eliminates the primary xenoreactive epitope
- Introduction of H-transferase transgene to alter blood group antigen expression
- Insertion of human complement regulatory and anti-inflammatory transgenes
- First double-knockout (GalT−/−) pigs produced by PPL Therapeutics/University of Pittsburgh in 2002, serving as the platform for further modifications
3. Specific Clinical Data, Statistics, and Study Results
1992 — Baboon-to-Human Liver Transplantation (Starzl/Fung, Pittsburgh):
- Indication: Hepatitis B (universal reinfection post-transplant in the pre-antiviral era made human liver transplantation contraindicated)
- Immunosuppression: Prostaglandin E1, cyclophosphamide, prednisone, tacrolimus (FK506, experimental)
- Donor: 7-year-old male baboon, ~40 kg; liver weight ~450 g
- Patient 1 (Brian): Survived 72 days; died from invasive pulmonary aspergillosis (aspergilloma with angioinvasion, linked to a breach in room containment)
- Functional evidence of baboon liver activity: lactate clearance, coagulopathy correction, ammonia clearance, bile secretion, bilirubin normalization
- Uric acid profiling: Recipient uric acid fell to baboon range (<0.5 mg/dL) within one week, reflecting baboon uricase activity — confirming metabolic "baboonization"
- Serum transferrin electrophoresis: Conversion to baboon transferrin complement pattern within one week post-transplant
- Baboon CMV transmission: Detected in recipient blood by one month post-operatively using human CMV primers with a shifted molecular weight — suggesting either cross-species transmission or human-baboon CMV recombination
1993 — Pig-to-Human Liver Perfusion as Bridge (Makowka, Mount Sinai):
- Patient: 26-year-old woman, acute liver failure from autoimmune hepatitis, no human organ available
- Strategy: Anti-